Amgen's $1.9bn looks buried
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
GSK’s trio of cancer discontinuations
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
ESMO 2025 – bemarituzumab fails to convince
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
ESMO 2025 preview – Astellas's third Claudin18.2 shot
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
